title: [Safety Assessment of a Short Hydration Regimen for Outpatient Cisplatin-Based Chemotherapy].
abstract: BACKGROUND
  During administration of thecisplatin (CDDP)containing regimen, hospitalization is necessary to ensure adequate hydration. However, short hydration is widely used when administering CDDP in outpatient chemotherapy centers.
  
  
  METHODS
  To assess the safety of the administration of CDDP during short hydration, we retrospectively evaluated adverse events and complications in the outpatients who received CDDP during short hydration between April 2012 and December 2014 in our hospital.
  
  
  RESULTS
  Sixty patients received CDDP during short hydration. Eighteen patients with non-small cell lung cancer, 17 with gastric cancer, 10 with small cell lung cancer, 9 with cervical cancer, 4 with biliary tract cancer, 1 with endometrial cancer, and 1 with duodenal papilla cancer were retrospectively evaluated. Fifty-five patients completed CDDP treatment(including treatment until PD). The reasons for discontinuation of CDDP treatment were deterioration of general condition, ileus, pneumothorax, cholangitis, and rejection of oral rehydration. Hydronephrosis after CDDP treatment during short hydration(weekly CDDP regimen)was observed in 1 patient. No patient discontinued CDDP due to grade 3 or 4 adverse events.
  
  
  CONCLUSIONS
  No discontinuation of CDDP associated with a short hydration regimen suggests that it has enabled thesafeadministration of CDDP to outpatients.
authors.affiliation: Dept. of Pharmacy, Japanese Red Cross Nagoya Daini Hospital.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yoshida
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Kimata
authors.forename: Masato
authors.initials: M
authors.lastname: Suzuki
authors.forename: Toshiki
authors.initials: T
authors.lastname: Uchida
authors.forename: Osamu
authors.initials: O
authors.lastname: Yamamuro
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D005440:Fluid Therapy; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010045:Outpatients; D012189:Retrospective Studies
chemical_list: D002945:Cisplatin